Related Experiment Video
Updated: Feb 8, 2026

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
Published on: April 7, 2017
miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn
Guodong Liu1, Liandong Ji1, Mujing Ke2
1Department of Pancreatic Biliary Surgery, Xiangya Hospital, Central South University, Changsha, 410008, PR China.
Background:
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers and resistance to cytotoxic chemotherapy is the major cause of mortality in PDAC patients. miR-125a-3p was found to be down-regulated in PDAC cells; however, the function of miR-125a-3p in PDAC has been elusive. Here, we explored the role of miR-125a-3p in chemosensitivity in PDAC cells.
Methods:
We used qRT-PCR to detect miR-125a-3p expression in two PDAC cell lines. And we measured cell viability and apoptosis by MTT assay and flow cytometry, respectively. Scratch wound healing assay and transwell invasion assay were used to test the effects of miR-125a-3p and Fyn on cell EMT process. In addition, we validated the interaction of miR-125a-3p and Fyn by dual luciferase reporter assay. qRT-PCR and western blot were used to detect the mRNA and protein expressions of E-cadhrein, N-cadhrein, Snail and Fyn.
Results:
We found that miR-125a-3p was down-regulated in a time-dependent manner following treatment with gemcitabine in PDAC cells. Meanwhile, we found that overexpression of miR-125a-3p significantly increased chemosensitivity to gemcitabine and suppressed epithelial-mesenchymal transition (EMT) of PDAC cells. Mechanistically, miR-125a-3p directly targeted Fyn and decreased the expression of Fyn that functions to promote EMT process in PDAC. Furthermore, overexpression of Fyn could partially reverse the effects of miR-125a-3p on chemosensitivity to gemcitabine.
Conclusion:
Our study is the first to show that miR-125a-3p is responsible for chemosensitivity in PDAC and could inhibit epithelial-mesenchymal transition by directly targeting Fyn. This provides a novel potential therapeutic strategy to overcome chemoresistance in PDAC.
Insights
This study reveals that miR-125a-3p enhances pancreatic cancer chemoresistance by targeting Fyn and inhibiting EMT. This offers a new therapeutic approach for pancreatic ductal adenocarcinoma (PDAC).
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with significant mortality due to chemoresistance.
- The role of miR-125a-3p in PDAC and its impact on chemosensitivity remained largely unknown.
Purpose of the Study:
- To investigate the function of miR-125a-3p in chemoresistance and epithelial-mesenchymal transition (EMT) in PDAC cells.
- To explore the underlying molecular mechanisms involving miR-125a-3p and its potential targets.
Main Methods:
- Quantitative real-time PCR (qRT-PCR) to assess miR-125a-3p expression.
- MTT assay and flow cytometry for cell viability and apoptosis.
- Scratch wound healing and Transwell invasion assays to evaluate EMT.
- Dual luciferase reporter assay to confirm direct targeting of Fyn by miR-125a-3p.
- Western blot to analyze protein expression levels.
Main Results:
- miR-125a-3p expression decreased in PDAC cells following gemcitabine treatment.
- Overexpression of miR-125a-3p enhanced sensitivity to gemcitabine and suppressed EMT.
- miR-125a-3p directly targets Fyn, reducing its expression and subsequent EMT promotion.
- Fyn overexpression partially reversed the chemosensitizing effects of miR-125a-3p.
Conclusions:
- miR-125a-3p plays a crucial role in chemosensitivity in PDAC.
- miR-125a-3p inhibits EMT by directly targeting Fyn.
- This finding presents a potential therapeutic strategy to overcome chemoresistance in PDAC.
Related Concept Videos
Phase Transitions
Feedback Inhibition
Properties of Transition Metals
Cooperative Allosteric Transitions
Phase Transitions: Vaporization and Condensation
Phase Transitions: Sublimation and Deposition

